{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:01:36Z","timestamp":1781661696271,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["archives-pmr.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Physical Medicine and Rehabilitation"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.apmr.2021.10.027","type":"journal-article","created":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T09:45:47Z","timestamp":1638092747000},"page":"1205-1209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits"],"prefix":"10.1016","volume":"103","author":[{"given":"Rashid","family":"Kazerooni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Verduzco-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apmr.2021.10.027_bib0001","unstructured":"Centers for Medicare & Medicaid Services. Available at:https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/Downloads\/ForecastSummary.pdf. Accessed May 1, 2020."},{"key":"10.1016\/j.apmr.2021.10.027_bib0002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2146\/ajhp140276","article-title":"Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia","volume":"72","author":"Kazerooni","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.apmr.2021.10.027_bib0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CEOR.S76141","article-title":"Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom","volume":"7","author":"Abogunrin","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.apmr.2021.10.027_bib0004","first-page":"478","article-title":"Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population","volume":"27","author":"Kazerooni","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.apmr.2021.10.027_bib0005","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.apmr.2021.10.027_bib0006","unstructured":"Centers for Medicare & Medicaid Services, Medicare provider utilization and payment data: physician and other supplier. Available at:https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Medicare-Provider-Charge-Data\/Physician-and-Other-Supplier. Accessed February 1, 2021."},{"key":"10.1016\/j.apmr.2021.10.027_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/toxins8030065","article-title":"Conversion Ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice","volume":"8","author":"Scaglione","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.apmr.2021.10.027_bib0008","unstructured":"Centers for Medicare & Medicaid Services, Medicare part B discarded drug units report. Available at: https:\/\/www.cms.gov\/research-statistics-data-systems\/cms-drug-spending\/medicare-part-b-discarded-drug-units-report. Accessed February 1, 2021."},{"key":"10.1016\/j.apmr.2021.10.027_bib0009","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.apmr.2020.04.001","volume":"102","author":"Lo","year":"2021","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2021.10.027_bib0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/STROKEAHA.109.558619","article-title":"Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event","volume":"41","author":"Lundstr\u00f6m","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.apmr.2021.10.027_bib0011","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.pmrj.2009.06.004","article-title":"Value-based physician reimbursement: challenges and opportunities for physical medicine and rehabilitation","volume":"1","author":"Rattray","year":"2009","journal-title":"PM R"},{"key":"10.1016\/j.apmr.2021.10.027_bib0012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/tsr1902-115","article-title":"Evidence to practice: botulinum toxin in the treatment of spasticity post stroke","volume":"19","author":"Teasell","year":"2012","journal-title":"Top Stroke Rehabil"},{"key":"10.1016\/j.apmr.2021.10.027_bib0013","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s00415-011-5998-9","article-title":"Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study","volume":"258","author":"Burbaud","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.apmr.2021.10.027_bib0014","first-page":"97","article-title":"Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries","volume":"5","author":"Roze","year":"2012","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.apmr.2021.10.027_bib0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2147\/CEOR.S320212","article-title":"Real-world six-year national cost-minimization analysis of incobotulinumtoxinA and onabotulinumtoxinA in the VA\/DoD healthcare systems","volume":"13","author":"Kazerooni","year":"2021","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.apmr.2021.10.027_bib0016","first-page":"205","article-title":"A retrospective cost analysis of patients who switched from onabotulinumtoxinA to incobotulinumtoxinA in a private neurology practice","volume":"13","author":"Karschney","year":"2020","journal-title":"Am Health Drug Benefits"}],"container-title":["Archives of Physical Medicine and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003999321016051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003999321016051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T07:12:12Z","timestamp":1757747532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003999321016051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0003999321016051"],"URL":"https:\/\/doi.org\/10.1016\/j.apmr.2021.10.027","relation":{},"ISSN":["0003-9993"],"issn-type":[{"value":"0003-9993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits","name":"articletitle","label":"Article Title"},{"value":"Archives of Physical Medicine and Rehabilitation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apmr.2021.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Congress of Rehabilitation Medicine.","name":"copyright","label":"Copyright"}]}}